eprintid: 61043
rev_number: 1
eprint_status: archive
userid: 1
dir: disk0/00/06/10/43
datestamp: 2026-05-26 15:52:09
lastmod: 2026-05-26 15:52:09
status_changed: 2026-05-26 15:52:09
type: article
metadata_visibility: show
sword_depositor: 1
creators_name: Mullokulov, Javohir
creators_name: Akhmedov, Khalmurad
title: NOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIES
ispublished: pub
note: Imported from Universal Publishings (OAI id oai:ojs.pkp.sfu.ca:article/14971)
abstract: Reactive Arthritis (ReA) is an immune-mediated form of spondyloarthritis, often triggered by genitourinary or gastrointestinal infections. Current therapeutic strategies rely mainly on NSAIDs and cs-DMARDs, with biologics reserved for refractory disease. However, limited progress has been made in exploring novel targeted agents. Iguratimod 25 mg, an oral immunomodulatory drug approved for rheumatoid arthritis in Asia, has demonstrated anti-inflammatory and cytokine-suppressive properties, but evidence in ReA is scarce
date: 2025-12-08
date_type: published
publisher: "Research Science and Innovation house" LLC
official_url: https://universalpublishings.com/index.php/jusr/article/view/14971
id_number: oai:ojs.pkp.sfu.ca:article/14971
full_text_status: none
publication: Journal of Universal Science Research
citation:   Mullokulov, Javohir, Akhmedov, Khalmurad  (2025) NOVEL TREATMENT APPROACHES IN REACTIVE ARTHRITIS: CLINICAL AND CYTOKINE RESPONSES TO IGURATIMOD 25 MG COMPARED WITH BIOLOGIC AND CONVENTIONAL THERAPIES.  Journal of Universal Science Research.